Novo Nordisk and Eli Lilly, two top drug makers behind weight-loss drugs known as GLP-1 receptor agonists, are faced with mounting lawsuits from patients who claim they were not adequately warned about the side effects, and lawyers handling these cases are considering “centralizing” these suits in federal court in Louisiana, according to Reuters.
